TAO Synergies Inc. (TAOX)
NASDAQ: TAOX · Real-Time Price · USD
8.41
-0.49 (-5.51%)
At close: Jul 25, 2025, 4:00 PM
8.59
+0.18 (2.14%)
After-hours: Jul 25, 2025, 4:50 PM EDT
TAO Synergies Employees
TAO Synergies had 4 employees as of December 31, 2024. The number of employees decreased by 1 or -20.00% compared to the previous year.
Employees
4
Change (1Y)
-1
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$3,241,366
Market Cap
11.70M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | -1 | -20.00% |
| Dec 31, 2023 | 5 | 0 | - |
| Dec 31, 2022 | 5 | 1 | 25.00% |
| Dec 31, 2021 | 4 | 0 | - |
| Dec 31, 2020 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TAOX News
- 24 days ago - TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today - PRNewsWire
- 4 weeks ago - Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy - PRNewsWire
- 4 weeks ago - Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - PRNewsWire
- 6 weeks ago - Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token - PRNewsWire
- 7 months ago - Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength - PRNewsWire
- 11 months ago - Synaptogenix Announces $5.0 Million Financing - PRNewsWire
- 1 year ago - Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury - PRNewsWire
- 1 year ago - Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis - PRNewsWire